The FDA granted AstraZeneca a Priority Review for its blockbuster oncology drug, Imfinzi (durvalumab), combined with chemotherapy, for treatment of patients with locally advanced or metastatic biliary tract cancer (BTC), a rare cancer affecting the bile ducts and gallbladder.
Source: Drug Industry Daily